Stock Alert: Immunic Shares Jump 56% After Hours

Shares of Immunic Inc. (IMUX) climbed over 56% in after-hours trading on April 21, after the company announced that its lead asset, IMU-838, a selective oral DHODH inhibitor, has successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

More specifically, IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with coronavirus disease 2019 (COVID-19). In cellular assays, IMU-838 demonstrated this antiviral activity at concentrations which are well below the blood concentrations associated with IMU-838 dosing regimens studied in ongoing and previous clinical trials.

These positive results have encouraged Immunic to prepare a clinical development program for IMU-838 as a potential treatment option for patients with COVID-19 and potential other, future viral pandemics, the company said.

The stock has been trading in the range of $4.19 - $19.50 for the past one year, and closed Tuesday's regular trade at $8.56, up 73 cents or 9.32%. IMUX further gained $4.84 or 56.54% in the after-hours trading session.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT